** Shares of Mayne Pharma Group MYX.AX soar 13.3% to A$5.30, their highest level since December 3, 2024
** Stock heads for a fourth consecutive session of gains, among top gainers in the ASX All Ordinaries index .AORD
** Speciality pharmaceutical firm says it expects 1H25 underlying EBITDA between A$30 million ($18.76 million) and A$32 million, up to four-fold jump from last year's A$8 million
** Revenue forecast between A$210 million and A$215 million, up to 14% growth
** Co expects to see continued growth in 2H25
** More than 112,000 shares change hands, vs the 30-day average of about 95,000 shares
** MYX up 6.8% this year, including day's moves
($1 = 1.5995 Australian dollars)
(Reporting by Sameer Manekar in Bengaluru)
((Sameer.Manekar@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。